MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
417.32
-1.14
-0.27%
Closed 17:40 03/27 EDT
OPEN
420.30
PREV CLOSE
418.46
HIGH
420.42
LOW
412.65
VOLUME
905.45K
TURNOVER
0
52 WEEK HIGH
448.40
52 WEEK LOW
307.93
MARKET CAP
107.80B
P/E (TTM)
30.03
1D
5D
1M
3M
1Y
5Y
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
NASDAQ · 22h ago
Wall Street Lunch: Florida Bans Social Media For Under 14
Florida signs bill requiring parental consent for minors to create social media accounts. McDonald's will start selling Krispy Kreme doughnuts this year. Maersk chartered vessel that brought down Baltimore bridge. UPS looks to return to growth with plans to sell doughnuts nationwide.
Seeking Alpha · 1d ago
Biotech Roundtable: Is CRISPR all its cracked up to be?
CRISPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. The FDA approved the first CRISPR product for the US market last fall. Is CRisPR overhyped? Which companies are most attractive right now in the space? Seeking Alpha biotech analysts Stephen Ayers and Edmund Ingham weigh in.
Seeking Alpha · 1d ago
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEvY in approved countries. Private insurers are showing interest in covering the treatment, providing further support for its commercial launch. I continue to hold a buy rating on CrisprTherapeutics.
Seeking Alpha · 2d ago
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
NASDAQ · 3d ago
Weekly Report: what happened at VRTX last week (0318-0322)?
Weekly Report · 3d ago
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
NASDAQ · 5d ago
Analyst Issues Sell Rating for Vertex Pharmaceuticals Amid Intensifying Drug Market Competition
TipRanks · 6d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Webull offers Vertex Pharmaceuticals Incorporated stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.